Wall Street Experts
ver. ZuMIgo(08/25)
Prognozy (mln) dla Apellis Pharmaceuticals, Inc.
| Okres |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
765.87 |
937.49 |
1,213.51 |
1,371.45 |
1,603.25 |
| Przychód Δ r/r |
0.00% |
22.41% |
29.44% |
13.01% |
16.90% |
| Przychód (min) |
694.25 |
786.40 |
1,209.42 |
1,219.16 |
1,425.22 |
| Przychód (max) |
906.71 |
1,192.09 |
1,217.60 |
1,620.90 |
1,894.86 |
| EBITDA (średnia) |
-642.99 |
-787.07 |
-1,018.81 |
-1,151.41 |
-1,346.01 |
| EBIT (średnia) |
-643.34 |
-787.50 |
-1,019.37 |
-1,152.04 |
-1,346.75 |
| EBIT % |
-84.00% |
-84.00% |
-84.00% |
-84.00% |
-84.00% |
| Zysk netto (średni) |
-241.42 |
-70.15 |
170.52 |
189.11 |
325.53 |
| Zysk netto % |
-31.52% |
-7.48% |
14.05% |
13.79% |
20.30% |
| EPS (średnia) |
-1.95 |
-0.62 |
1.06 |
1.53 |
2.63 |
| Liczba analityków (Przychody) |
15 |
21 |
18 |
8 |
11 |
| Liczba analityków (EPS) |
12 |
16 |
16 |
15 |
14 |
| symbol |
APLS |
APLS |
APLS |
APLS |
APLS |